Daraxonrasib is an oral targeted cancer medicine sold under the brand name Rasonque. It works against active RAS proteins, which are signaling proteins that can help cancer cells grow and survive.
In August 2026, the FDA approved daraxonrasib for certain adults with metastatic pancreatic adenocarcinoma. It is intended for people who have already received at least one systemic cancer treatment or who are not candidates for treatment with multiple systemic medicines.
Daraxonrasib is taken by mouth once a day and may be continued while it is controlling the cancer and side effects remain manageable. Treatment should be prescribed and monitored by an oncology team because the medicine can cause serious side effects in addition to more common reactions.
Indications for use
Daraxonrasib is FDA-approved for adults with metastatic pancreatic adenocarcinoma, meaning pancreatic gland cancer that has spread to other parts of the body.
It can be used in adults who:
-
Have already received at least one previous systemic treatment for metastatic pancreatic adenocarcinoma, or
-
Are not candidates for multiagent systemic therapy, which involves treatment with more than one systemic cancer medicine.
Daraxonrasib should not be described as a treatment for every type or stage of pancreatic cancer. Its current FDA approval applies specifically to the metastatic pancreatic adenocarcinoma population described above.
The FDA-approved indication does not require a confirmed RAS mutation or a companion diagnostic test before treatment. However, molecular testing of the tumor may still be useful when planning overall cancer treatment.
How to take it
The recommended dose of daraxonrasib is 300 mg by mouth once daily.
Treatment is generally continued until:
-
The cancer progresses, or
-
Side effects become unacceptable.
Daraxonrasib should be taken at approximately the same time each day. It can be taken with or without food.
The tablets should be swallowed whole and should not be chewed, crushed, split, or otherwise broken before taking them.
Available forms
Daraxonrasib is available as oral tablets in:
-
100 mg
-
150 mg
The prescribed 300 mg daily dose can therefore be supplied using the appropriate combination of tablets. The exact number and strength of tablets should follow the prescription provided by the treating oncology team.
Missed dose
If a dose is missed, it can be taken when remembered unless more than 4 hours have passed since the usual dose time.
If more than 4 hours have passed, the missed dose should be skipped and the next dose should be taken at the regularly scheduled time. Two doses should not be taken together to make up for a missed dose.
Possible side effects
Daraxonrasib can cause mild to serious side effects. Common reactions that may occur during treatment include:
-
Skin rash
-
Diarrhea
-
Swelling or sores in the mouth
-
Nausea
-
Fatigue or weakness
-
Vomiting
-
Abdominal pain
-
Swelling of the arms or legs
-
Reduced appetite
-
Bleeding
Side effects should be assessed by the oncology team because treatment may sometimes need to be interrupted, adjusted, or discontinued depending on the type and severity of the reaction.
Serious side effects
Serious risks associated with daraxonrasib include:
-
Severe skin reactions
-
Stomatitis and other significant mouth problems
-
Severe diarrhea
-
Gastrointestinal perforation, which is a hole in the wall of the stomach or intestine
-
Interstitial lung disease or pneumonitis, which involves inflammation or injury in the lungs
-
Harm to an unborn baby
New or worsening symptoms during treatment, particularly serious digestive, skin, or breathing symptoms, require medical assessment.
Contraindications for use
Daraxonrasib has important safety precautions, particularly concerning pregnancy, breastfeeding, serious adverse reactions, and potential drug interactions.
A complete medication review is important before treatment because the prescribing information contains guidance regarding drug interactions and situations in which treatment may need to be avoided or modified.
Pregnancy and breastfeeding
Daraxonrasib can harm an unborn baby.
People who can become pregnant should have a pregnancy test before starting treatment and should use effective contraception while taking daraxonrasib and for 1 week after the final dose.
Male patients with partners who can become pregnant should also use effective contraception during treatment and for 1 week after the final dose.
Breastfeeding is not recommended during daraxonrasib treatment or for 1 week after the final dose because of the potential risk to the infant.